Last reviewed · How we verify
BAY 86-7660,levomefolate calcium
Levomefolate calcium is a folate analog that acts as a methyl donor in one-carbon metabolism.
Levomefolate calcium is a folate analog that acts as a methyl donor in one-carbon metabolism. Used for Prevention of neural tube defects during pregnancy, Treatment of megaloblastic anemia.
At a glance
| Generic name | BAY 86-7660,levomefolate calcium |
|---|---|
| Sponsor | Bayer |
| Drug class | Folate analog |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
It is involved in the synthesis of purines and pyrimidines, and is used to prevent or treat folate deficiency.
Approved indications
- Prevention of neural tube defects during pregnancy
- Treatment of megaloblastic anemia
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAY 86-7660,levomefolate calcium CI brief — competitive landscape report
- BAY 86-7660,levomefolate calcium updates RSS · CI watch RSS
- Bayer portfolio CI